- Low-dose radiation may confer net cancer protection: Hwang et al. 2006 data show 40 % lower overall cancer incidence except for elevated leukemia and thyroid cancer in people under 30, prompting discussion of hormetic trade-offs.  
- Rapid paralysis recovery demonstrated: real-time neural-ensemble decoding from peripheral nerves plus EMG re-implantation and electrical-stimulation rehab restored voluntary leg control to four complete spinal-cord-injury patients within days; polyethylene-glycol cord fusion and 1-year frost-bite nerve-regrowth timelines were cited as complementary repair strategies.  
- A DIY sub-micron lithography system is being prototyped that pairs a Raspberry-Pi-controlled OpenLabTools microscope with a Blu-ray optical sled for photoresist exposure; printed micro-grids tracked by USB video provide real-time motion feedback to correct stage errors, while nine-photodiode pinhole arrays could sense nanometer-scale drift and tilt.  
- Electronics pedagogy critique: 555-timer kits teach little real electronics; instead, beginners should start with $2–$4 microcontrollers (ATTiny26, Cypress PSoC) and hands-on analog experiments; open lab tools compared include the $20 LPC-Link2 (80 MSPS ADC for SDR), $120 Digilent Analog Discovery, and Bus Pirate for protocol debugging.  
- Historical arc of bio-electronics traced from Galvani vs. Volta’s 1790s “animal electricity” experiments through Helmholtz’s 1849 nerve-conduction timing, illustrating how circuit thinking emerged from frog-muscle twitches and Leyden-jar shocks.  
- Chronic Lyme disease debate: advocates argue PCR and antibody tests miss cystic latent infections, while skeptics claim absence of Borrelia DNA indicates misdiagnosis; DNRS (Dynamic Neural Retraining System) was dismissed as rebranded cognitive-behavioral therapy for multiple-chemical-sensitivity and chronic-fatigue patients.  
- Open, censorship-resistant marketplaces (e.g., OpenBazaar) proposed to distribute low-cost lab equipment and circumvent FDA/Amazon/eBay shutdowns; FDA-reform ideas include separating safety and efficacy, lowering trial costs for startups, and applying uniform safety-proportional rules to drugs, supplements, and cosmetics.